NASDAQ:TRDA Entrada Therapeutics (TRDA) Stock Price, News & Analysis $5.19 -0.11 (-2.08%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$5.18 -0.02 (-0.29%) As of 08/8/2025 05:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Entrada Therapeutics Stock (NASDAQ:TRDA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Entrada Therapeutics alerts:Sign Up Key Stats Today's Range$5.05▼$5.4750-Day Range$5.19▼$8.3252-Week Range$4.98▼$21.79Volume308,342 shsAverage Volume212,911 shsMarket Capitalization$196.96 millionP/E RatioN/ADividend YieldN/APrice Target$25.67Consensus RatingBuy Company Overview Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts. Read More Entrada Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreTRDA MarketRank™: Entrada Therapeutics scored higher than 41% of companies evaluated by MarketBeat, and ranked 645th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingEntrada Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEntrada Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Entrada Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Entrada Therapeutics are expected to decrease in the coming year, from $1.12 to ($3.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Entrada Therapeutics is -2.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Entrada Therapeutics is -2.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEntrada Therapeutics has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Entrada Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.81% of the float of Entrada Therapeutics has been sold short.Short Interest Ratio / Days to CoverEntrada Therapeutics has a short interest ratio ("days to cover") of 9.6.Change versus previous monthShort interest in Entrada Therapeutics has recently increased by 4.00%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEntrada Therapeutics does not currently pay a dividend.Dividend GrowthEntrada Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.81% of the float of Entrada Therapeutics has been sold short.Short Interest Ratio / Days to CoverEntrada Therapeutics has a short interest ratio ("days to cover") of 9.6.Change versus previous monthShort interest in Entrada Therapeutics has recently increased by 4.00%, indicating that investor sentiment is decreasing. News and Social Media1.1 / 5News Sentiment-1.00 News SentimentEntrada Therapeutics has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Entrada Therapeutics this week, compared to 2 articles on an average week.Search Interest2 people have searched for TRDA on MarketBeat in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Entrada Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,782,000.00 in company stock.Percentage Held by InsidersOnly 8.11% of the stock of Entrada Therapeutics is held by insiders.Percentage Held by Institutions86.39% of the stock of Entrada Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Entrada Therapeutics' insider trading history. Receive TRDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Entrada Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TRDA Stock News HeadlinesVentures V. L.P. 5Am Sells 6,935 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) StockJuly 12, 2025 | insidertrades.comEntrada Therapeutics Reports Second Quarter 2025 Financial ResultsAugust 6 at 7:00 AM | globenewswire.comMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI. | Brownstone Research (Ad)5am Ventures v sells Entrada Therapeutics (TRDA) stock for $202kJuly 13, 2025 | investing.comEntrada therapeutics (TRDA) director Parmar sells $202k in stockJuly 13, 2025 | investing.comEntrada Therapeutics (TRDA) 10% owners sell $866k in stockJuly 3, 2025 | investing.comEntrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of DirectorsJune 3, 2025 | globenewswire.comEntrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 2, 2025 | globenewswire.comSee More Headlines TRDA Stock Analysis - Frequently Asked Questions How have TRDA shares performed this year? Entrada Therapeutics' stock was trading at $17.29 at the beginning of the year. Since then, TRDA shares have decreased by 70.0% and is now trading at $5.19. How were Entrada Therapeutics' earnings last quarter? Entrada Therapeutics, Inc. (NASDAQ:TRDA) issued its quarterly earnings results on Wednesday, August, 6th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.86) by $0.18. The company had revenue of $1.98 million for the quarter, compared to analyst estimates of $8.17 million. Entrada Therapeutics had a negative trailing twelve-month return on equity of 17.81% and a negative net margin of 92.30%. When did Entrada Therapeutics IPO? Entrada Therapeutics (TRDA) raised $182 million in an IPO on Friday, October 29th 2021. The company issued 9,075,000 shares at $19.00-$21.00 per share. Who are Entrada Therapeutics' major shareholders? Top institutional shareholders of Entrada Therapeutics include Geode Capital Management LLC (1.66%), Los Angeles Capital Management LLC (0.12%), AlphaQuest LLC (0.10%) and Corton Capital Inc. (0.08%). Insiders that own company stock include Bioventures 2018 LP Mpm, Ventures V LP 5Am, Kush Parmar, Dipal Doshi, Natarajan Sethuraman, Nathan J Dowden, Kory James Wentworth and Peter S Kim. View institutional ownership trends. How do I buy shares of Entrada Therapeutics? Shares of TRDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Entrada Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Entrada Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Palo Alto Networks (PANW) and Invesco QQQ (QQQ). Company Calendar Last Earnings8/06/2025Today8/08/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TRDA CIK1689375 Webwww.entradatx.com Phone857-520-9158FaxN/AEmployees110Year FoundedN/APrice Target and Rating Average Price Target for Entrada Therapeutics$25.67 High Price Target$29.00 Low Price Target$20.00 Potential Upside/Downside+394.5%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$65.63 million Net Margins-92.30% Pretax Margin-96.76% Return on Equity-17.81% Return on Assets-14.55% Debt Debt-to-Equity RatioN/A Current Ratio18.64 Quick Ratio21.88 Sales & Book Value Annual Sales$210.78 million Price / Sales0.93 Cash Flow$1.55 per share Price / Cash Flow3.34 Book Value$10.00 per share Price / Book0.52Miscellaneous Outstanding Shares37,950,000Free Float34,875,000Market Cap$196.96 million OptionableOptionable Beta-0.12 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:TRDA) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entrada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entrada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.